The short answer
GLP-1 therapy can restart ovulation in PCOS, often a cycle or two before your period looks regular. If you are sexually active and not planning a pregnancy, start contraception the same week you start the medication. Two details decide which method fits.
Why fertility comes back
PCOS anovulation is driven by insulin resistance and excess weight. GLP-1 receptor agonists improve insulin secretion, and at weight-loss doses they drop body weight: in STEP 1 (semaglutide 2.4 mg, n=1,961 adults with obesity, no diabetes) mean loss was −14.9% at 68 weeks versus −2.4% on placebo; SURMOUNT-1 (tirzepatide, n=2,539) reached −20.9% at the 15 mg dose versus −3.1%.
Neither trial enrolled women for PCOS or measured ovulation. Read those numbers as the size of the weight change that tends to restore cycles, not as a fertility result. That weight loss plus improved insulin sensitivity lowers circulating androgens and lets ovulation resume — that is mechanism, not a measured endpoint. The practical trap is timing: you can ovulate, and conceive, before bleeding becomes regular enough to notice a pattern.
Contraception from day one
Pill, hormonal IUD, implant, ring, or barrier are all reasonable. Do not let an irregular history do the work — the cycle may already be more regular than you think. And build the exit into the plan: GLP-1 medications are stopped before a planned pregnancy, so decide with your clinician when to come off if conceiving is the goal.
Stopping the drug can undo it
The metabolic benefit lasts only as long as you take the medication. In STEP 4 (Rubino et al., JAMA 2021), people who stopped semaglutide at week 20 regained much of what they had lost, while those who continued kept losing. In SURMOUNT-4 (Aronne et al., JAMA 2024), stopping tirzepatide after 36 weeks led to about 14% regain over the next year versus roughly 5.5% further loss on those who stayed on it. The PCOS relevance is direct: if you come off the drug and regain weight, insulin resistance and anovulation can return — so plan contraception around real intentions, not around a cycle that may not stay regular.
The absorption question is not the same for both drugs
Every GLP-1 slows gastric emptying — the same mechanism behind early nausea. For oral contraceptives, that matters differently by drug, and this is where the two medications part ways.
Tirzepatide’s FDA label carries an oral-contraceptive warning: switch to a non-oral method, or add a barrier backup, for 4 weeks after starting and after each dose increase, because a pharmacokinetic study showed reduced pill exposure. Injectable semaglutide carries no such warning on its label. If you are on a non-oral method — IUD, implant, or injection — the question does not arise for either drug.
What we recommend at Zappy
The cleanest setup on a GLP-1 you are not trying to conceive on is a hormonal IUD or the implant. Both sidestep the absorption question entirely, and neither depends on daily timing during titration, which is exactly when nausea is worst. Combined or progestin-only pills are fine too — on tirzepatide, just add barrier backup for the 4 weeks after each titration step.
For reference, standard semaglutide titration starts at 0.25 mg weekly and steps roughly every 4 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), slower if side effects hit. On tirzepatide, each of those steps opens a new 4-week window for the pill caveat.
The open question
No trial has measured pregnancy or live-birth rates when contraceptive method varies alongside GLP-1 dose escalation. The contraceptive guidance is pharmacokinetic — measured pill blood levels — not outcome data. Until that trial exists, the conservative move for pill users on tirzepatide is the backup method, and the simplest move for everyone is a method that does not route through the gut. If you are not sure which fits your history, start with the intake and a clinician will map it to your titration plan.
